SAN FRANCISCO, CA--(Marketwired - September 09, 2016) - With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp. (
Included in this article is: DURECT Corp.
In an Aug. 29 research report reiterating Laidlaw's investment thesis for the company, Molloy outlined imminent catalysts for three candidates in DURECT Corp.'s pipeline.
The PDUFA (Prescription Drug User Fee Act) date for Remoxy is up first, with Molloy calling the drug "[a] former greenkeeper, now, about to become the Masters champion." Though the abuse-resistant formulation of oxycodone has been "circling FDA approval for two putts, we believe Remoxy is on track to finally get the tap in on the third go at FDA approval this September 25th," the analyst wrote.
Continue reading this article: Three Shots on Goal in Q4/16 for DURECT Corp.
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURE:
The following companies mentioned in this article are sponsors of Streetwise Reports: DURECT Corp. The companies mentioned in this article were not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Please see the end of the article for the complete disclosure: Three Shots on Goal in Q4/16 for DURECT Corp.
Contact Information:
Jim Patrick
Publisher